Stock ELAB ELEVAI LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Elevai Labs Inc.

Equities

ELAB

US28622K1043

Market Closed - Nasdaq
Other stock markets
 21:30:00 31/05/2024 BST 		5-day change 1st Jan Change
0.66 USD +0.84% Intraday chart for Elevai Labs Inc. -1.21% -63.90%
05-19 Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
05-15 Elevai Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
Elevai Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries
Elevai Labs Inc. Announces Executive Changes
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Enters into Exclusive Licensing Agreement with MOA Life Plus Co., Ltd to Develop and Commercialize Two Novel Assets for the Treatment of Obesity and Muscle Loss Prevention
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
Elevai Labs Signs Exclusive Distribution Deal for Taiwan
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Elevai Labs, Inc. Enters the Taiwan Market with Signing of 5Th International Distribution Agreement in 14 Months
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
Elevai Labs, Inc. Launches E-Commerce Portal
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELAB Stock
  4. News Elevai Labs Inc.
  5. Other languages